Search

Displaying results 3051 - 3060 of 10000 in total
  1. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

    Synonyms: Polymyxin EProducts: Poly-E Water Soluble Powder 750MIU/kg
  2. Drug

    Bifonazole

    go.drugbank.com/drugs/DB04794
    Approved

    Bifonazole is an azole antifungal drug.

  3. Drug

    Antrafenine

    go.drugbank.com/drugs/DB01419
    Approved

    Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.

  4. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications of a rare inherited disease called vascular Ehlers–Danlos syndrome. … Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

    Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
  5. Drug

    Centanafadine

    go.drugbank.com/drugs/DB14841
    ApprovedInvestigational

    [L63806] Its mechanism in ADHD is unclear, but its efficacy may be mediated by this triple reuptake inhibition, which increases the availability of all three neurotransmitters in pathways involved in attention … reuptake inhibitor, positioning it as a new mechanistic option in a condition where response varies widely between individuals and many patients remain symptomatic on existing treatment.

  6. Drug

    Aminosalicylic acid

    go.drugbank.com/drugs/DB00233
    ApprovedInvestigational

    An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.

  7. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [L47915] All five putative N-glycosylation sites on each polypeptide chain predicted by the primary sequence can be occupied with carbohydrates and exhibit some degree of chain heterogeneity, including

    Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIAL
  8. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965].

  9. Drug

    Magnesium citrate

    go.drugbank.com/drugs/DB11110
    ApprovedInvestigational

    [L2831] It is also considered as an active ingredient in over-the-counter products.[L1113] … [T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.

    Mixtures: PEN Prep PlusProducts: PEN Prep
  10. Drug

    Florbetapir F-18

    go.drugbank.com/drugs/DB09149
    ApprovedInvestigational

    The radionucleide fluorine-18 was chosen as it has a half life of 110 minutes allowing it to accumulate sufficiently in the brain before undergoing positon emission decay. … radiopharmaceutical compound containing the radionuclide fluorine-18 bound to the compound florbetapir, a molecule that binds with high affinity to beta amyloid plaque, a peptide that plays a key role in

    Synonyms: 4-{(E)-2-[6-(2-{2-[2-(18F)fluoroethoxy]ethoxy}ethoxy)pyridin-3-yl]ethenyl}-N-methylaniline